Compounds > 9-fluoreneacetic acid
Page last updated: 2024-11-06

9-fluoreneacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-Fluoreneacetic acid, also known as flufenamic acid, is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It was first synthesized in the 1960s and has been used clinically for the treatment of pain and inflammation associated with various conditions, including rheumatoid arthritis, osteoarthritis, and dysmenorrhea. 9-Fluoreneacetic acid exerts its effects by inhibiting the production of prostaglandins, which are inflammatory mediators. It is typically administered orally and has a moderate duration of action. The compound's mechanism of action, pharmacokinetic properties, and potential side effects have been extensively studied in various preclinical and clinical trials. Further research is ongoing to explore its potential therapeutic applications and to develop safer and more effective derivatives.'

9-fluoreneacetic acid: used for tagging silica-based derivatization reagents in HPLC [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID94852
CHEMBL ID44381
SCHEMBL ID42370
MeSH IDM0210840

Synonyms (35)

Synonym
AC-4879
9h-fluorene-9-acetic acid
bdbm50034798
(9h-fluoren-9-yl)-acetic acid
AKOS015840841
6284-80-6
fluorene-9-acetic acid ,
nsc5255
nsc-5255
9-fluoreneacetic acid, 99%
9-fluoreneacetate
CHEMBL44381 ,
9-fluoreneacetic acid
F0330
2-(9h-fluoren-9-yl)acetic acid
nsc 5255
9h-fluorene-9-aceticacid
FT-0636067
BP-21045
fluoren-9-acetic acid
WFSMJMTYIMFHPV-UHFFFAOYSA-N
SCHEMBL42370
Q-101167
mfcd00013262
DTXSID50212015
(9h-fluoren-9-yl)acetic acid
EN300-1833850
9-fluoreneacetic acid;fluorene-9-acetic acid
Q63395574
STR04895
AMY32679
T72735
2-(9h-fluoren-9-yl)aceticacid
CS-0144028
SY048674
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)8.90000.00041.877310.0000AID34961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID34961Inhibitory activity against purified rat lens aldose reductase (RLAR)1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Molecular modeling studies of aldose reductase inhibitors.
AID91169In vitro ability to inhibit the adhesion of neutrophil activated by tumor necrosis factor (alpha-TNF) to serum-coated plastic wells.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-phenylpropionic acid
3-phenylpropionic acid: RN given refers to parent cpd. 3-phenylpropionic acid : A monocarboxylic acid that is propionic acid substituted at position 3 by a phenyl group.		1.9910benzenes;
monocarboxylic acid		antifungal agent;
human metabolite;
plant metabolite
cadaverine
[no description available]		1.9810alkane-alpha,omega-diamineDaphnia magna metabolite;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite
glyceraldehyde
Glyceraldehyde: An aldotriose containing the propionaldehyde structure with hydroxy groups at the 2- and 3-positions. It is involved in the formation of ADVANCED GLYCOSYLATION END PRODUCTS.. glyceraldehyde : An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.. aldose : Aldehydic parent sugars (polyhydroxy aldehydes H[CH(OH)]nC(=O)H, n >= 2) and their intramolecular hemiacetals.		1.9910aldotriosefundamental metabolite
alrestatin
alrestatin: aldose reductase inhibitor; RN given refers to parent cpd; structure		1.9810
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		1.9810adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
ponalrestat
[no description available]		1.9810phthalazines
fr 74366
[no description available]		2.3920
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		1.9910azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		1.9910thiazolidine
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.940benzenes;
phenyl acetates
1-(9-fluorenyl)methyl chloroformate
1-(9-fluorenyl)methyl chloroformate: used for tagging silica-based derivatization reagents in HPLC		1.9810
1-pyrenebutyrate
1-pyrenebutyrate: fluorescent probe; RN given refers to 1-pyrenebutyrate		1.9910
n-(9h-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine
N-(9H-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine: RN given refers to the (L-Leu)-isomer		1.9810
ad 5467
AD 5467: structure given in first source		1.9810
imidazolidines
[no description available]		1.9910azacycloalkane;
imidazolidines;
saturated organic heteromonocyclic parent
rhodanine
2-mercaptothiazolinone: metabolite in urine from persons exposed to CS2; structure		1.9910thiazolidinone
epalrestat
epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.		2.3920monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
n-(fluorenyl-9-methoxycarbonyl)leucine
N-(fluorenyl-9-methoxycarbonyl)leucine: a leumedin; RN given for (L)-isomer		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials